Idioma:

Rationale and design of the IRON‐CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy

Martens, Pieter ; Dupont, Matthias ; Dauw, Jeroen ; Somers, Frauke ; Herbots, Lieven ; Timmermans, Philippe ; Verwerft, Jan ; Mullens, Wilfried

ESC Heart Failure, 2019-12, Vol.6 (6), p.1208-1215 [Periódico revisado por pares]

England: John Wiley & Sons, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Rationale and design of the IRON‐CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy
Autor: Martens, Pieter ; Dupont, Matthias ; Dauw, Jeroen ; Somers, Frauke ; Herbots, Lieven ; Timmermans, Philippe ; Verwerft, Jan ; Mullens, Wilfried
Assuntos: Administration, Intravenous ; Adult ; Angina pectoris ; Cardiac remodelling ; Cardiac Resynchronization Therapy - adverse effects ; Contractility ; Double-Blind Method ; Ejection fraction ; Female ; Ferric Compounds - administration & dosage ; Ferric Compounds - pharmacology ; Ferric Compounds - therapeutic use ; Heart Failure ; Hemoglobin ; Humans ; Investigations ; Iron ; Iron - deficiency ; Laboratories ; Male ; Maltose - administration & dosage ; Maltose - analogs & derivatives ; Maltose - pharmacology ; Maltose - therapeutic use ; Prospective Studies ; Proteins ; Study Design ; Study Designs ; Ventricular Remodeling - drug effects
É parte de: ESC Heart Failure, 2019-12, Vol.6 (6), p.1208-1215
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
Descrição: Aims Iron deficiency is common in heart failure with reduced ejection fraction (HFrEF). In patients with cardiac resynchronization therapy (CRT), it is associated with a diminished reverse remodelling response and poor functional improvement. The latter is partially related to a loss in contractile force at higher heart rates (negative force–frequency relationship). Methods and results The effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy (IRON‐CRT) trial is a multicentre, prospective, randomized, double‐blind controlled trial in HFrEF patients who experienced incomplete reverse remodelling (defined as a left ventricular ejection fraction below <45%) at least 6 months after CRT. Additionally, patients need to have iron deficiency defined as a ferritin below 100 μg/L irrespective of transferrin saturation or a ferritin between 100 and 300 μg/L with a transferrin saturation <20%. Patients will be randomized to either intravenous ferric carboxymaltose (dose based according to Summary of Product Characteristics) or intravenous placebo. The primary objective is to evaluate the effect of ferric carboxymaltose on metrics of cardiac reverse remodelling and contractility, measured by the primary endpoint, change in left ventricular ejection fraction assessed by three‐dimensional (3D) echo from baseline to 3 month follow‐up and the secondary endpoints change in left ventricular end‐systolic and end‐diastolic volume. The secondary objective is to determine if ferric carboxymaltose is capable of improving cardiac contractility in vivo, by assessing the force–frequency relationship through incremental biventricular pacing. A total of 100 patients will be randomized in a 1:1 fashion. Conclusions The IRON‐CRT trial will determine the effect of ferric carboxymaltose on cardiac reverse remodelling and rate‐dependent cardiac contractility in HFrEF patients.
Editor: England: John Wiley & Sons, Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 5 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Rationale and design of the IRON‐CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy

Martens, Pieter ; Dupont, Matthias ; Dauw, Jeroen ; Somers, Frauke ; Herbots, Lieven ; Timmermans, Philippe ; Verwerft, Jan ; Mullens, Wilfried

England: John Wiley & Sons, Inc

Buscando em bases de dados remotas. Favor aguardar.